MarketCap
Facebook
X
Telegram
Alpine Immune Sciences Net Income | ALPN
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Alpine Immune Sciences
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -32.2 M | -57.8 M | -50.3 M | -27.9 M | -41.9 M | -36.5 M | -7.78 M | -1.23 M | -369 K | -14.7 M | -16.2 M | -9.57 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -369 K | -57.8 M | -24.7 M |
Quarterly Net Income Alpine Immune Sciences
| 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -17.9 M | - | -11.7 M | -13.2 M | -13.3 M | - | -13.3 M | -18.1 M | -7.53 M | - | -13.5 M | -11 M | -10.6 M | - | -6.14 M | -9.93 M | -5.53 M | - | -11.5 M | -11.9 M | -12.4 M | - | -12.1 M | -7.91 M | -5.31 M | - | 2.12 M | -3.71 M | -8.92 M | -7.71 M | -7.43 M | -8.48 M | -7.84 M | -6.56 M | -6.09 M | -10.2 M | -4.31 M | -3.49 M | -2.63 M | -4.19 M | -4.35 M | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.12 M | -18.1 M | -8.72 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Cyclerion Therapeutics
CYCN
|
-3.18 M | $ 34.99 | 3.77 % | $ 147 M |  USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
-65.8 M | $ 9.84 | -8.29 % | $ 269 M |  Israel |
 |
Alector
ALEC
|
-143 M | $ 1.83 | -0.27 % | $ 188 M | USA |
 |
Inventiva S.A.
IVA
|
-184 M | $ 3.71 | 3.06 % | $ 222 M |  France |
 |
Johnson & Johnson
JNJ
|
26.8 B | $ 263.81 | -1.46 % | $ 635 B | USA |
 |
argenx SE
ARGX
|
1.29 B | $ 873.71 | -0.23 % | $ 53.6 B |  Niderland |
 |
Arcutis Biotherapeutics
ARQT
|
-16.1 M | $ 31.2 | -3.11 % | $ 3.97 B | USA |
 |
ObsEva SA
OBSV
|
-58.4 M | - | -15.52 % | $ 10.5 M |  Schweiz |
 |
Cocrystal Pharma
COCP
|
-8.83 M | $ 0.95 | 4.17 % | $ 10.7 M | USA |
 |
Ascendis Pharma A/S
ASND
|
-228 M | $ 243.37 | 0.16 % | $ 14.7 B |  Danmark |
 |
Kronos Bio
KRON
|
-86.1 M | - | 1.49 % | $ 50.8 M | USA |
 |
Lineage Cell Therapeutics
LCTX
|
-63.5 M | $ 1.0 | 1.52 % | $ 230 M | USA |
 |
Landos Biopharma
LABP
|
-21.9 M | - | 0.58 % | $ 144 M | USA |
 |
PhaseBio Pharmaceuticals
PHAS
|
-131 M | - | 7.4 % | $ 6.29 M | USA |
 |
Legend Biotech Corporation
LEGN
|
-297 M | $ 19.27 | 1.96 % | $ 7.1 B | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
124 M | $ 303.53 | -1.39 % | $ 5.87 B | USA |
 |
Longeveron
LGVN
|
-22.7 M | $ 1.6 | 0.63 % | $ 28.1 B | USA |
 |
Lipocine
LPCN
|
-9.63 M | $ 1.44 | -1.37 % | $ 7.85 M | USA |
 |
Provention Bio
PRVB
|
-114 M | - | - | $ 2.37 B | USA |
 |
Poseida Therapeutics
PSTX
|
-123 M | - | - | $ 857 M | USA |
 |
Liquidia Corporation
LQDA
|
-68.9 M | $ 42.65 | 7.46 % | $ 3.67 B | USA |
 |
Annovis Bio
ANVS
|
-28.9 M | $ 1.0 | -0.07 % | $ 20.6 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
-61.4 M | - | - | $ 231 M | USA |
 |
Atara Biotherapeutics
ATRA
|
32.7 M | $ 8.59 | -8.91 % | $ 108 M | USA |
 |
Lexicon Pharmaceuticals
LXRX
|
-50.3 M | $ 1.42 | -4.7 % | $ 516 M | USA |
 |
Reata Pharmaceuticals
RETA
|
-312 M | - | - | $ 6.29 B | USA |
 |
PolarityTE
PTE
|
-7.83 M | - | -0.82 % | $ 1.78 M | USA |
 |
Moleculin Biotech
MBRX
|
-33.6 M | $ 6.5 | 10.36 % | $ 7.7 M | USA |
 |
Mirum Pharmaceuticals
MIRM
|
-23.4 M | $ 80.39 | -3.26 % | $ 4.04 B | USA |
 |
MediciNova
MNOV
|
12 M | $ 1.39 | -1.31 % | $ 68.2 M | USA |
 |
Merck & Co.
MRK
|
18.3 B | $ 145.27 | -1.34 % | $ 363 B | USA |
 |
Maravai LifeSciences Holdings
MRVI
|
-131 M | $ 7.32 | 3.54 % | $ 1.06 B | USA |
 |
Virpax Pharmaceuticals
VRPX
|
-12.1 M | - | -45.12 % | $ 2.85 M | USA |
 |
Axsome Therapeutics
AXSM
|
-183 M | $ 145.04 | -7.07 % | $ 7.22 B | USA |
 |
Matinas BioPharma Holdings
MTNB
|
-10.3 M | $ 1.71 | 0.88 % | $ 9.36 M | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
-78.5 M | $ 4.05 | -1.94 % | $ 53.9 M | USA |
 |
Stealth BioTherapeutics Corp
MITO
|
-52.5 M | - | - | $ 23.9 M | USA |
 |
Neurocrine Biosciences
NBIX
|
479 M | $ 142.7 | -0.41 % | $ 14.2 B | USA |
 |
Satsuma Pharmaceuticals
STSA
|
-70.1 M | - | -0.9 % | $ 36.5 M | USA |
 |
BioCardia
BCDA
|
-8.23 M | $ 0.92 | -0.83 % | $ 6.13 M | USA |
 |
Kodiak Sciences
KOD
|
-230 M | $ 87.63 | 2.16 % | $ 4.66 B | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
264 M | $ 7.65 | -1.67 % | $ 1.61 B | USA |
 |
SpringWorks Therapeutics
SWTX
|
-258 M | - | - | $ 3.48 B | USA |
 |
Nektar Therapeutics
NKTR
|
-164 M | $ 37.22 | -3.7 % | $ 628 M | USA |
 |
Nkarta
NKTX
|
-104 M | $ 1.79 | 2.87 % | $ 132 M | USA |
 |
NanoViricides
NNVC
|
-8.22 M | $ 1.4 | 0.72 % | $ 28.3 M | USA |
 |
Trevena
TRVN
|
-40.3 M | - | -46.58 % | $ 31.8 M | USA |
 |
Nurix Therapeutics
NRIX
|
-264 M | $ 25.34 | -0.67 % | $ 2.2 B | USA |
 |
Denali Therapeutics
DNLI
|
-513 M | $ 18.41 | -1.34 % | $ 3.18 B | USA |
 |
Oncorus
ONCR
|
-77.4 M | - | -8.54 % | $ 3.19 M | USA |